Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.
Cytonics attracts 900 new investors as 35% of existing shareholders reinvest
The clinical-stage biotechnology company completed approximately 1,500 individual investments in the round, including roughly 900 first-time backers. Of the pre-raise shareholder base, 35% chose to invest again, according to the company. The raise brings cumulative funds secured through Regulation A and Regulation Crowdfunding offerings to $27 million.
Proceeds fund CYT-108 development ahead of Phase 1b/2a osteoarthritis trial
Cytonics will direct the capital toward continued development of CYT-108, its investigational engineered alpha-2-macroglobulin (A2M) biologic designed to inhibit multiple classes of destructive proteases involved in cartilage degradation. The company has completed a first-in-human Phase 1 study and is now progressing regulatory, manufacturing, and clinical planning required to launch a Phase 1b/2a study in knee osteoarthritis.
CEO frames retail-funded model as alternative to institutional biotech financing
"Biotechnology is usually financed by a small circle of institutions. We have built Cytonics differently,